Inke strengthens presence in China at the 92nd API China – Guangzhou

Inke recently participated in the 92nd edition of API China, held in Guangzhou, reaffirming its commitment to the fast-evolving Chinese pharmaceutical landscape. As a key event in mainland China — and one that is gaining regional importance across East Asia — API China provided a strategic platform for Inke to connect with partners and gain first-hand insight into market trends.

As a global specialist in inhalation APIs, Inke’s attendance focused on identifying new opportunities, sharing expertise, and reinforcing its strategic positioning in the region.

Key insights from API China 2025:

• Chinese pharmaceutical companies are increasingly focused on innovative drug development, creating new collaboration opportunities.

• The FDF license-in business, particularly through innovator and 505(b)(2) models, is gaining momentum in China.

• The inhalation drug market in China is expanding rapidly, driven by both local demand and international aspirations.

• Leading Chinese inhalation FDF players are showing growing interest in entering international markets.

• Nebulized products are facing strong competition due to lower technical and regulatory barriers and GPO tender pressures — yet demand remains high.

• The majority of current DPI inhalation projects are generic, with fewer initiatives focused on 505(b)(2) development.

• The regulatory environment for inhalation APIs and FDFs is becoming increasingly clear, supporting innovation and market access.

Inke continues to grow its presence in Asia, leveraging decades of experience in particle engineering, regulatory compliance, and tailored support to meet the specific needs of inhalation therapy developers.

We look forward to the next API China event, taking place from November 12–14, 2025 in Chongqing.